Continuous lenalidomide treatment for newly diagnosed multiple myeloma
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F12%3A13167" target="_blank" >RIV/00216208:11110/12:13167 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/12:00061483 RIV/65269705:_____/12:#0001642 RIV/00064165:_____/12:13167
Result on the web
<a href="http://dx.doi.org/10.1056/NEJMoa1112704" target="_blank" >http://dx.doi.org/10.1056/NEJMoa1112704</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Continuous lenalidomide treatment for newly diagnosed multiple myeloma
Original language description
Lenalidomide has tumoricidal and immunomodulatory activity against multiple myeloma. This double-blind, multicenter, randomized study compared melphalan-prednisone-lenalidomide induction followed by lenalidomide maintenance (MPR-R) with melphalan-prednisone-lenalidomide (MPR) or melphalan-prednisone (MP)
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
New England Journal of Medicine
ISSN
0028-4793
e-ISSN
—
Volume of the periodical
366
Issue of the periodical within the volume
19
Country of publishing house
US - UNITED STATES
Number of pages
11
Pages from-to
1759-1769
UT code for WoS article
000303817000005
EID of the result in the Scopus database
—